-
公开(公告)号：US07569593B2
公开(公告)日：2009-08-04
申请号：US10956880
申请日：2004-10-01
申请人： Nathanael Schiander Gray , Jiqing Jiang , Yi Liu , Ruo Steensma
发明人： Nathanael Schiander Gray , Jiqing Jiang , Yi Liu , Ruo Steensma
IPC分类号： A61K31/4439 , C07D401/04
CPC分类号： C07D401/04 , C07D401/02 , C07D405/12 , C07D405/14
摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, lck, SAPK2α, p38, TGFβ, KDR, c-Kit, b-RAF, c-RAF, FLT1 and FLT4 kinases.
摘要翻译： 本发明提供了一类新颖的化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法，特别是涉及Abl，BCR-Abl异常活化的疾病或病症 ，PDGF-R，lck，SAPK2alpha，p38，TGFbeta，KDR，c-Kit，b-RAF，c-RAF，FLT1和FLT4激酶。
-
2.发明授权2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders 有权2，4-嘧啶二胺可用于治疗肿瘤性疾病，炎症和免疫系统疾病公开(公告)号：US07893074B2
公开(公告)日：2011-02-22
申请号：US10568367
申请日：2004-08-13
申请人： Carlos Garcia-Echeverria , Takanori Kanazawa , Eiji Kawahara , Keiichi Masuya , Naoko Matsuura , Takahiro Miyake , Osamu Ohmori , Ichiro Umemura , Ruo Steensma , Greg Chopiuk , Jiqing Jiang , Yongqin Wan , Qiang Ding , Qiong Zhang , Nathanael Schiander Gray , Donald Karanewsky
发明人： Carlos Garcia-Echeverria , Takanori Kanazawa , Eiji Kawahara , Keiichi Masuya , Naoko Matsuura , Takahiro Miyake , Osamu Ohmori , Ichiro Umemura , Ruo Steensma , Greg Chopiuk , Jiqing Jiang , Yongqin Wan , Qiang Ding , Qiong Zhang , Nathanael Schiander Gray , Donald Karanewsky
IPC分类号： C07D239/48 , A61K31/506
CPC分类号： C07D239/48 , C04B35/632 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14
摘要： Novel pyrimidine derivatives of formula I to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
摘要翻译： 式I的新型嘧啶衍生物用于其制备方法，它们作为药物的用途以及包含它们的药物组合物。
-
3.发明申请2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders 有权2，4-嘧啶二胺可用于治疗新生儿疾病，炎症和免疫系统疾病公开(公告)号：US20080132504A1
公开(公告)日：2008-06-05
申请号：US10568367
申请日：2004-08-13
申请人： Carlos Garcia-Echeverria , Takanori Kanazawa , Eiji Kawahara , Keiichi Masuya , Naoko Matsuura , Takahiro Miyake , Osamu Ohmori , Ichiro Umemura , Ruo Steensma , Greg Chopiuk , Jiqing Jiang , Yongqin Wan , Qiang Ding , Qiong Zhang , Nathanael Schiander Gray , Donald Karanewsky
发明人： Carlos Garcia-Echeverria , Takanori Kanazawa , Eiji Kawahara , Keiichi Masuya , Naoko Matsuura , Takahiro Miyake , Osamu Ohmori , Ichiro Umemura , Ruo Steensma , Greg Chopiuk , Jiqing Jiang , Yongqin Wan , Qiang Ding , Qiong Zhang , Nathanael Schiander Gray , Donald Karanewsky
IPC分类号： A61K31/506 , A61K31/497 , A61K31/535 , A61P29/00 , A61P35/00 , A61P37/00 , C07D239/48 , C07D403/12 , C07D413/12
CPC分类号： C07D239/48 , C04B35/632 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14
摘要： Novel pyrimidine derivatives of formula I to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them
摘要翻译： 式I的新型嘧啶衍生物用于其制备方法，它们作为药物的用途以及包含它们的药物组合物
-
4.发明申请2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS 审中-公开2,4-PYRIMININEDIAMINES有用的治疗神经疾病，炎症和免疫系统疾病公开(公告)号：US20110098280A1
公开(公告)日：2011-04-28
申请号：US12984519
申请日：2011-01-04
申请人： Carlos Garcia-Echeverria , Takanori Kanazawa , Eiji Kawahara , Keiichi Masuya , Naoko Matsuura , Takahiro Miyake , Osamu Ohmori , Ichiro Umemura , Ruo Steensma , Greg Chopiuk , Jiqing Jiang , Yongqin Wan , Qiang Ding , Qiong Zhang , Nathanael Schiander Gray , Donald Karanewsky
发明人： Carlos Garcia-Echeverria , Takanori Kanazawa , Eiji Kawahara , Keiichi Masuya , Naoko Matsuura , Takahiro Miyake , Osamu Ohmori , Ichiro Umemura , Ruo Steensma , Greg Chopiuk , Jiqing Jiang , Yongqin Wan , Qiang Ding , Qiong Zhang , Nathanael Schiander Gray , Donald Karanewsky
IPC分类号： A61K31/505 , C07D239/48 , C07D405/12 , A61K31/506 , C07D403/12 , C07D413/12 , A61K31/5377 , C07D401/12 , C07D417/14 , A61K31/541 , C07D401/14 , C07D498/04 , A61K31/5383 , C07D413/14 , A61K31/55 , A61P35/00
CPC分类号： C07D239/48 , C04B35/632 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14
摘要： Novel pyrimidine derivatives of formula I to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
摘要翻译： 式I的新型嘧啶衍生物用于其制备方法，它们作为药物的用途以及包含它们的药物组合物。
-
公开(公告)号：US20090258910A1
公开(公告)日：2009-10-15
申请号：US12492081
申请日：2009-06-25
申请人： Nathanael S. Gray , Jiqing Jiang , Yi Liu , Ruo Steensma
发明人： Nathanael S. Gray , Jiqing Jiang , Yi Liu , Ruo Steensma
IPC分类号： A61K31/4439 , C07D401/04 , A61P35/00
CPC分类号： C07D401/04 , C07D401/02 , C07D405/12 , C07D405/14
摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, lck, SAPK2α, p38, TGFβ, KDR, c-Kit, b-RAF, c-RAF, FLT1 and FLT4 kinases.
摘要翻译： 本发明提供了一类新颖的化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法，特别是涉及Abl，BCR-Abl异常活化的疾病或病症 ，PDGF-R，lck，SAPK2alpha，p38，TGFbeta，KDR，c-Kit，b-RAF，c-RAF，FLT1和FLT4激酶。
-
公开(公告)号：US07449582B2
公开(公告)日：2008-11-11
申请号：US10961646
申请日：2004-10-08
申请人： Qiang Ding , Yongping Xie , Nathanael S. Gray , Shuli You , Greg Chopiuk , Jiqing Jiang , Yi Liu , Ruo Steensma , Xing Wang , Taebo Sim
发明人： Qiang Ding , Yongping Xie , Nathanael S. Gray , Shuli You , Greg Chopiuk , Jiqing Jiang , Yi Liu , Ruo Steensma , Xing Wang , Taebo Sim
IPC分类号： C07D215/38 , C07D471/02 , C07D251/38
CPC分类号： C07D471/04
摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, CSK, JNK1, JNK2, PDGF-R, p38, p70S6K, TGFβ, SRC, EGFR, c-Kit, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6 and SAPK2β kinases.
摘要翻译： 本发明提供了一类新颖的化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法，特别是涉及Abl，BCR-Abl异常活化的疾病或病症 ，CSK，JNK1，JNK2，PDGF-R，p38，p70S6K，TGFbeta，SRC，EGFR，c-Kit，trkB，FGFR3，Fes，Lck，Syk，RAF，MKK4，MKK6和SAPK2β激酶。
-
公开(公告)号：US20050187230A1
公开(公告)日：2005-08-25
申请号：US10961646
申请日：2004-10-08
申请人： Qiang Ding , Yongping Xie , Nathanael Gray , Shuli You , Greg Chopiuk , Jiqing Jiang , Yi Liu , Ruo Steensma , Xing Wang , Taebo Sim
发明人： Qiang Ding , Yongping Xie , Nathanael Gray , Shuli You , Greg Chopiuk , Jiqing Jiang , Yi Liu , Ruo Steensma , Xing Wang , Taebo Sim
IPC分类号： A61K20060101 , A61K31/44 , A61K31/47 , A61K31/4706 , A61K31/4745 , A61K31/519 , C07D215/16 , C07D471/00 , C07D471/02
CPC分类号： C07D471/04
摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, CSK, JNK1, JNK2, PDGF-R, p38, p70S6K, TGFβ, SRC, EGFR, c-Kit, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6 and SAPK2β kinases.
摘要翻译： 本发明提供了一类新颖的化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法，特别是涉及Abl，BCR-Abl异常活化的疾病或病症 ，CSK，JNK1，JNK2，PDGF-R，p38，p70S6K，TGFbeta，SRC，EGFR，c-Kit，trkB，FGFR3，Fes，Lck，Syk，RAF，MKK4，MKK6和SAPK2β激酶。
-
公开(公告)号：US20050209285A1
公开(公告)日：2005-09-22
申请号：US10956880
申请日：2004-10-01
申请人： Nathanael Gray , Jiqing Jiang , Yi Liu , Ruo Steensma
发明人： Nathanael Gray , Jiqing Jiang , Yi Liu , Ruo Steensma
IPC分类号： A61K20060101 , A61K31/4439 , C07D401/02 , C07D401/04 , C07D405/14 , C07D43/02
CPC分类号： C07D401/04 , C07D401/02 , C07D405/12 , C07D405/14
摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, lck, SAPK2α, p38, TGFβ, KDR, c-Kit, b-RAF, c-RAF, FLT1 and FLT4 kinases.
摘要翻译： 本发明提供了一类新颖的化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法，特别是涉及Abl，BCR-Abl异常活化的疾病或病症 ，PDGF-R，lck，SAPK2alpha，p38，TGFbeta，KDR，c-Kit，b-RAF，c-RAF，FLT1和FLT4激酶。
-
公开(公告)号：US08178526B2
公开(公告)日：2012-05-15
申请号：US12664651
申请日：2008-06-12
申请人： Badry Bursulaya , Dai Cheng , Jiqing Jiang , Donald S. Karanewsky , Yi Liu , Shifeng Pan , Yongqin Wan , Xia Wang , Yun Feng Xie , Yang Yang
发明人： Badry Bursulaya , Dai Cheng , Jiqing Jiang , Donald S. Karanewsky , Yi Liu , Shifeng Pan , Yongqin Wan , Xia Wang , Yun Feng Xie , Yang Yang
IPC分类号： C07D413/02 , C07D413/14 , A61K31/536 , A61K31/551
CPC分类号： C07D413/14 , C07D413/02
摘要： The invention provides a novel class of compounds of formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or dysregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1,4,5-trisphosphate 3-kinase B (ITPKb).
摘要翻译： 本发明提供了一类新颖的式（I）化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调B细胞活性相关的疾病或病症的方法，特别是涉及异常活化的疾病或病症 肌醇1,4,5-三磷酸3-激酶B（ITPKb）。
-
公开(公告)号：US20120202782A1
公开(公告)日：2012-08-09
申请号：US13445644
申请日：2012-04-12
申请人： Badry Bursulaya , Dai Cheng , Jiqing Jiang , Donald S. Karanewsky , Yi Liu , Shifeng Pan , Yongqin Wan , Xia Wang , Yun Feng Xie , Yang Yang
发明人： Badry Bursulaya , Dai Cheng , Jiqing Jiang , Donald S. Karanewsky , Yi Liu , Shifeng Pan , Yongqin Wan , Xia Wang , Yun Feng Xie , Yang Yang
IPC分类号： A61K31/536 , A61K31/551 , A61K31/496 , A61K31/4985 , C07D487/08 , A61K31/538 , C07D401/14 , A61K31/517 , A61P37/06 , A61P29/00 , A61P19/02 , A61P17/06 , A61P7/06 , A61P35/00 , C07D413/14
CPC分类号： C07D413/14 , C07D413/02
摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or dysregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1,4,5-trisphosphate 3-kinase B (ITPKb).
摘要翻译： 本发明提供了一类新颖的化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的B细胞活性有关的疾病或病症的方法，特别是涉及肌醇1,4异常活化的疾病或病症， 5-三磷酸3-激酶B（ITPKb）。
-
-
-
-
-
-
-
-
-
搜索结果
23 条记录 (耗时 0.03 秒)
